Head of Laboratory
Douglas Hanahan email@example.com
Head of Laboratory
Douglas Hanahan, born in Seattle, Washington, USA, received a bachelor’s degree in Physics from MIT (1976), and a Ph.D. in Biophysics from Harvard (1983). He worked at Cold Spring Harbor Laboratory in New York (1978-88) initially as a graduate student and then as a group leader. From 1988-2010 he was on the faculty of the Department of Biochemistry & Biophysics at UCSF in San Francisco. He has been elected to the American Academy of Arts & Sciences (2007), the Institute of Medicine (USA) (2008), the US National Academy of Science (2009), and EMBO (2010). In 2011, Hanahan received an honorary degree from the University of Dundee (UK).
Ehud Drori firstname.lastname@example.org
Ehud graduated from San Francisco State University (1996) with a BS in Biochemistry. He worked as a technician researching drugs to treat diabetes I & II at Terrapin Tech Inc. in South San Francisco (1996-1997). He then worked as lab technician SRAIII in Dr. Carol Basbaum’s lab doing basic research in respiratory diseases at the University of California, San Francisco (1997-2001). He joined the laboratory of Dr. Douglas Hanahan in 2001 as the lab manager and has been at EPFL-ISREC since 2010.
Post-docs & Research Staff
Mélanie Louise Tichet email@example.com
Mélanie received her PhD degree from the University of Nice Sophia-Antipolis (France) in 2013 for her work on the matricellular protein SPARC in the metastatic dissemination of melanoma, a lethal form of skin cancer. After this, she performed the first post-doctoral training in her PhD lab where she continued her work on melanoma. In 2015, she joined the Hanahan lab at the EPFL School of Life Sciences. She is interested in investigating stromal influences in tumor development using mouse models of cancer.
Stephan Wullschleger firstname.lastname@example.org
Pre-Clinical Trials Manager, Scientist
Stephan graduated in Biochemistry (2000) at the University of Basel. In 2004, he received his PhD in Biochemistry from the Biozentrum in Basel where he characterized the biochemical properties of TOR complex 2 (TORC2). After his PhD studies he performed post-doctoral training at the MRC Protein Phosphorylation Unit in Dundee (UK) where he analyzed signal transduction pathways implicated in diabetes and cancer. In 2011, he joined the Hanahan lab and he is studying proteins involved in tumor invasion and metastasis employing pharmacological as well as genetic approaches in mouse models of cancer.
Qiqun Zeng email@example.com
Qiqun received her Bachelor degree in biological science (2007) from Sichuan University, China. In 2012, she obtained her PhD degree in cell biology from the Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. During and after her PhD studies, she studied the role and underlying mechanism of the cell adhesion molecule CD146 in breast cancer metastasis and tumor angiogenesis. In 2014, she joined the Hanahan lab in the ISREC Institute, at the EPFL School of Life Sciences, to study the roles and regulation of glutamate-NMDAR signaling in cancer progression.
Agnieszka Chryplewicz firstname.lastname@example.org
Agnieszka earned her B.Eng. and M.Sc. degrees in Biotechnology from Wroclaw University of Science and Technology, Poland. After her studies she received Fulbright scholarship to train in the lab of Dr. Ernst Lengyel at the University of Chicago and work on identifying drivers of ovarian cancer metastasis. She joined the Hanahan lab in 2018 as a PhD student at the EPFL School of Life Sciences. Her current work is focused on combinatorial treatments in mouse models of glioblastoma.
Sadegh Saghafinia email@example.com
Sadegh graduated in Chemical Engineering (2012) at the Sharif University of Technology, Iran. In 2012 he started his master studies in Biotechnology at EPFL. Currently, he is doing his master thesis in Hanahan lab, working on the role of miRNAs in metastasis of PanNET.
Mei-Wen Peng firstname.lastname@example.org
Mei-Wen graduated from National Chung-Hsing university (Taiwan, 2007) with a master in Molecular Biology. She worked in medical research centers focused on cancer and tuberculosis using animal models. She has been at Hanahan lab since 2011.
Sylvie André Baflast email@example.com
Sylvie André Baflast obtained her diploma of Technician in Biomedical Analyses (2003) at The School of Laboratory Profession (ECLAB) of Geneva. She worked at the ISREC institute at Epalinges in the laboratory of the Professor Richard Iggo where she was mainly involved in a study on the role of p53 mutations in breast cancer in a clinical trial. In 2005, she helped to set up his laboratory at the University of St Andrews in Scotland. During this period, she gained experiences in gene expression and adenoviruses production before joining the group of Professor Michel Aguet at EPFL in 2007. Besides supporting the laboratory, she also performed independent research on the BCL9 project in colon cancer. Since June 2013, Sylvie has been working as a technician in the laboratory of Prof. Hanahan. She is currently working with Dr. Krisztian Homicsko on the melanoma’s project.
Sebastien Lamy firstname.lastname@example.org
Krisztian Homicsko email@example.com
Scientific Academic Guest
Krisztian graduated in medicine with summa cum laude from the Semmelweis Medical University, Budapest, Hungary in 2001. In 2002 he received his M.Sc. at the University of Geneva in Medical Biology. He obtained a PhD in the Swiss Institute of Experimental Cancer Research in 2006 working in the laboratory of Prof. Richard Iggo on replicating tumor selective oncolytic viruses targeting colorectal cancer. After a short postdoctoral training at the University of St Andrews, Scotland UK, in the lab of Prof. Iggo, he performed medical training at several locations including the Ninewells University Hospital Dundee, UK, and at the Hospital of the Curie Institute, Paris, France. He finished his training in medical oncology at the University Hospital of Lausanne (CHUV), Lausanne, Switzerland. He joined the Hanahan lab in 2011 and works part time in the lab and in the clinical activity of the melanoma clinic in the department of Oncology at CHUV. His projects focus on understanding the molecular mechanisms of resistance to targeted therapies in melanoma using a genetically engineered mouse model of melanoma.